Cargando…

Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?

Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varricchi, Gilda, Senna, Gianenrico, Loffredo, Stefania, Bagnasco, Diego, Ferrando, Matteo, Canonica, Giorgio Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344894/ https://www.ncbi.nlm.nih.gov/pubmed/28344579 http://dx.doi.org/10.3389/fimmu.2017.00242

Ejemplares similares

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
por: Bagnasco, Diego, et al.
Publicado: (2017)

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati, Marco, et al.
Publicado: (2019)

Therapeutic interventions in severe asthma
por: Canonica, Giorgio Walter, et al.
Publicado: (2016)

Role of biologics in severe eosinophilic asthma – focus on reslizumab
por: Pelaia, Girolamo, et al.
Publicado: (2016)

Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy
por: Brusselle, Guy, et al.
Publicado: (2017)

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs
por: Varricchi, Gilda, et al.
Publicado: (2016)

Update on new biologics for intractable eosinophilic asthma: impact of reslizumab
por: Sahota, Jagdeep, et al.
Publicado: (2018)

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
por: Walsh, Garry M
Publicado: (2013)

Personalized Medicine in Allergy
por: Ferrando, Matteo, et al.
Publicado: (2017)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Successful treatment of refractory eosinophilic fasciitis with reslizumab
por: Mortezavi, Mahta, et al.
Publicado: (2020)

Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
por: Pérez de Llano, Luis A, et al.
Publicado: (2022)

Targeting eosinophils: severe asthma and beyond
por: Caminati, Marco, et al.
Publicado: (2019)

Reslizumab as add-on therapy in patients with refractory asthma
por: Virchow, J Christian, et al.
Publicado: (2020)

Reslizumab in the management of poorly controlled asthma: the data so far
por: Maselli, Diego Jose, et al.
Publicado: (2016)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Kent, Brian D., et al.
Publicado: (2020)

Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects
por: Máspero, Jorge
Publicado: (2017)

Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma
por: Bagnasco, Diego, et al.
Publicado: (2018)

The effectiveness of Reslizumab in severe asthma treatment: a real-world experience
por: Ibrahim, H., et al.
Publicado: (2019)

Type 2 immunity in asthma
por: Caminati, Marco, et al.
Publicado: (2018)

Biologics in Severe Eosinophilic Asthma: Three-Year Follow-Up in a SANI Single Center
por: Solidoro, Paolo, et al.
Publicado: (2022)

In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEV(1) reversibility
por: Virchow, J. Christian, et al.
Publicado: (2020)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
por: Puggioni, Francesca, et al.
Publicado: (2020)

Personalized and Precision Medicine in Asthma and Eosinophilic Esophagitis: The Role of T2 Target Therapy
por: Bagnasco, Diego, et al.
Publicado: (2023)

Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI
por: Senna, Gianenrico, et al.
Publicado: (2020)

Minimal clinically important difference for asthma endpoints: an expert consensus report
por: Bonini, Matteo, et al.
Publicado: (2020)

COVID-19, Eosinophils, and Biologicals for Severe Asthma
por: Lombardi, Carlo, et al.
Publicado: (2022)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients
por: Canonica, G. Walter, et al.
Publicado: (2015)

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma
por: Marone, Giancarlo, et al.
Publicado: (2019)

Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine
por: Dwivedi, Shailendra, et al.
Publicado: (2017)

Staging in bipolar disorder: one step closer to precision psychiatry
por: Fernandes, Brisa S., et al.
Publicado: (2017)

Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?
por: Agache, Ioana, et al.
Publicado: (2017)

Causes of Non-Adherence to Allergen-Specific Immunotherapy: A Foundation towards a Patient-Personalized Approach
por: Ridolo, Erminia, et al.
Publicado: (2023)

Fatal asthma; is it still an epidemic?
por: Vianello, Andrea, et al.
Publicado: (2016)

Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study
por: Vultaggio, Alessandra, et al.
Publicado: (2023)

Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry
por: Canonica, Giorgio Walter, et al.
Publicado: (2019)

Non-episodic Angioedema With Eosinophilia Successfully Treated With Reslizumab
por: Chu, Hyunwook, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hnj6bngt8if2j9gu6c2ug13klr